Quick Detail
Place of Origin
Brand Name
Jinlan
HS-CODE
-
Package & Delivery Lead Time
Package
1g,10g,20g,
Detailed Description
Description
Brensocatib is an oral, competitive, reversible inhibitor of DPP1. It blocks the activation of neutrophil serine proteases (NSPs: NE, PR3, CatG) during neutrophil maturation, reducing airway inflammation and structural damage in bronchiectasis.
Approved Indications
- Non‑cystic fibrosis bronchiectasis (NCFB) in patients ≥12 years with ≥2 exacerbations in the prior 12 months
Key Features
- First‑in‑class DPP1 inhibitor (FDA/EMA approved 2025)
- First FDA‑approved drug for NCFB
- Once‑daily oral dosing (10 mg / 25 mg)
- Reduces annual exacerbation rate by ~19% (ASPEN Phase III)EMA
- Slows FEV₁ decline vs placebo
Applications
API, intermediates, reference standards for R&D, generic registration, and commercial manufacturing.
China [CN] 
Click enlarge Image